Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data
Here, we report our 1-year follow-up data of stable ABO-incompatible kidney transplant recipients who converted from mycophenolate mofetil plus a standard dose of a calcineurin inhibitor to everolimus plus low exposure to calcineurin inhibitors. Our study included 17 recipients of ABO-incompatible k...
Gespeichert in:
| Veröffentlicht in: | Experimental and clinical transplantation 2019-04, Vol.17 (2), p.190-195 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 195 |
|---|---|
| container_issue | 2 |
| container_start_page | 190 |
| container_title | Experimental and clinical transplantation |
| container_volume | 17 |
| creator | Uchida, Junji Iwai, Tomoaki Nishide, Shunji Kabei, Kazuya Kuwabara, Nobuyuki Naganuma, Toshihide Kumada, Norihiko Takemoto, Yoshiaki Nakatani, Tatsuya |
| description | Here, we report our 1-year follow-up data of stable ABO-incompatible kidney transplant recipients who converted from mycophenolate mofetil plus a standard dose of a calcineurin inhibitor to everolimus plus low exposure to calcineurin inhibitors.
Our study included 17 recipients of ABO-incompatible kidney transplant procedures performed at our institution. At baseline and at 3 and 12 months after conversion, graft biopsies were performed to check for acute rejection and C4d deposition.
Treatment with everolimus was stopped due to adverse events in 8 patients (47.1%). Conversion to everolimus with calcineurin inhibitor minimization did not induce acute rejection or C4d deposition at 3 and 12 months after conversion in ABO-incompatible kidney transplant recipients in whom everolimus was maintained or stopped within 1 year after conversion.
Everolimus elicited no acute rejection and no C4d deposition, whether everolimus was maintained or stopped within 1 year after conversion, in ABO-incompatible kidney transplant recipients. |
| doi_str_mv | 10.6002/ect.2017.0200 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_ideal</sourceid><recordid>TN_cdi_idealonline_journals_IDEAL_90891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30198840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-10d4985ca1a3814739b93305ea60e81f4b45b70db2a696b2bb7dbf4f9d3c6c133</originalsourceid><addsrcrecordid>eNo9kc1u1DAURi0EoqPSJVvkHSsPduwkNrthOgMjpmrVnwUry3YcYeTYke0pyqv0aUk0wOpKn869-nQPAO8JXjcYV5-sKesKk3aNK4xfgVVFWIM4q9rXYEUoZgjzur4AVzk7jRlr24o1_C24oJgIzhlegZc752OB2xiebcouBvhQTt0E9ykO8GYycfxpQ_SqWHgTe1uchyXC3QxH74ZThm7ZUNpbuPlyiw7BxGFUxS3Bd9cFO8HHpEIevQoF3lvjRmdDyZ_hJig_ZZdh7CFBP6xKcB-9j7_R0wivVVHvwJte-Wyv_s5L8LTfPW6_oePt18N2c0SGClIQwR0TvDaKKMoJa6nQglJcW9Vgy0nPNKt1iztdqUY0utK67XTPetFR0xhC6SX4eL7rOqt8DN4FK3_FU5oLZnm43m2OUmAuyEyiM2lSzDnZXo7JDSpNkmC5CJGzELkIkYuQmf9w5seTHmz3n_73fvoHsSqIAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Uchida, Junji ; Iwai, Tomoaki ; Nishide, Shunji ; Kabei, Kazuya ; Kuwabara, Nobuyuki ; Naganuma, Toshihide ; Kumada, Norihiko ; Takemoto, Yoshiaki ; Nakatani, Tatsuya</creator><contributor>Haberal,Mehmet</contributor><creatorcontrib>Uchida, Junji ; Iwai, Tomoaki ; Nishide, Shunji ; Kabei, Kazuya ; Kuwabara, Nobuyuki ; Naganuma, Toshihide ; Kumada, Norihiko ; Takemoto, Yoshiaki ; Nakatani, Tatsuya ; the Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan ; Haberal,Mehmet</creatorcontrib><description>Here, we report our 1-year follow-up data of stable ABO-incompatible kidney transplant recipients who converted from mycophenolate mofetil plus a standard dose of a calcineurin inhibitor to everolimus plus low exposure to calcineurin inhibitors.
Our study included 17 recipients of ABO-incompatible kidney transplant procedures performed at our institution. At baseline and at 3 and 12 months after conversion, graft biopsies were performed to check for acute rejection and C4d deposition.
Treatment with everolimus was stopped due to adverse events in 8 patients (47.1%). Conversion to everolimus with calcineurin inhibitor minimization did not induce acute rejection or C4d deposition at 3 and 12 months after conversion in ABO-incompatible kidney transplant recipients in whom everolimus was maintained or stopped within 1 year after conversion.
Everolimus elicited no acute rejection and no C4d deposition, whether everolimus was maintained or stopped within 1 year after conversion, in ABO-incompatible kidney transplant recipients.</description><identifier>ISSN: 1304-0855</identifier><identifier>EISSN: 2146-8427</identifier><identifier>DOI: 10.6002/ect.2017.0200</identifier><identifier>PMID: 30198840</identifier><language>eng</language><publisher>Turkey: Başkent Üniversitesi</publisher><subject>Tıp</subject><ispartof>Experimental and clinical transplantation, 2019-04, Vol.17 (2), p.190-195</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-10d4985ca1a3814739b93305ea60e81f4b45b70db2a696b2bb7dbf4f9d3c6c133</citedby><cites>FETCH-LOGICAL-c391t-10d4985ca1a3814739b93305ea60e81f4b45b70db2a696b2bb7dbf4f9d3c6c133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30198840$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Haberal,Mehmet</contributor><creatorcontrib>Uchida, Junji</creatorcontrib><creatorcontrib>Iwai, Tomoaki</creatorcontrib><creatorcontrib>Nishide, Shunji</creatorcontrib><creatorcontrib>Kabei, Kazuya</creatorcontrib><creatorcontrib>Kuwabara, Nobuyuki</creatorcontrib><creatorcontrib>Naganuma, Toshihide</creatorcontrib><creatorcontrib>Kumada, Norihiko</creatorcontrib><creatorcontrib>Takemoto, Yoshiaki</creatorcontrib><creatorcontrib>Nakatani, Tatsuya</creatorcontrib><creatorcontrib>the Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan</creatorcontrib><title>Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data</title><title>Experimental and clinical transplantation</title><addtitle>Exp Clin Transplant</addtitle><description>Here, we report our 1-year follow-up data of stable ABO-incompatible kidney transplant recipients who converted from mycophenolate mofetil plus a standard dose of a calcineurin inhibitor to everolimus plus low exposure to calcineurin inhibitors.
Our study included 17 recipients of ABO-incompatible kidney transplant procedures performed at our institution. At baseline and at 3 and 12 months after conversion, graft biopsies were performed to check for acute rejection and C4d deposition.
Treatment with everolimus was stopped due to adverse events in 8 patients (47.1%). Conversion to everolimus with calcineurin inhibitor minimization did not induce acute rejection or C4d deposition at 3 and 12 months after conversion in ABO-incompatible kidney transplant recipients in whom everolimus was maintained or stopped within 1 year after conversion.
Everolimus elicited no acute rejection and no C4d deposition, whether everolimus was maintained or stopped within 1 year after conversion, in ABO-incompatible kidney transplant recipients.</description><subject>Tıp</subject><issn>1304-0855</issn><issn>2146-8427</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNo9kc1u1DAURi0EoqPSJVvkHSsPduwkNrthOgMjpmrVnwUry3YcYeTYke0pyqv0aUk0wOpKn869-nQPAO8JXjcYV5-sKesKk3aNK4xfgVVFWIM4q9rXYEUoZgjzur4AVzk7jRlr24o1_C24oJgIzhlegZc752OB2xiebcouBvhQTt0E9ykO8GYycfxpQ_SqWHgTe1uchyXC3QxH74ZThm7ZUNpbuPlyiw7BxGFUxS3Bd9cFO8HHpEIevQoF3lvjRmdDyZ_hJig_ZZdh7CFBP6xKcB-9j7_R0wivVVHvwJte-Wyv_s5L8LTfPW6_oePt18N2c0SGClIQwR0TvDaKKMoJa6nQglJcW9Vgy0nPNKt1iztdqUY0utK67XTPetFR0xhC6SX4eL7rOqt8DN4FK3_FU5oLZnm43m2OUmAuyEyiM2lSzDnZXo7JDSpNkmC5CJGzELkIkYuQmf9w5seTHmz3n_73fvoHsSqIAQ</recordid><startdate>201904</startdate><enddate>201904</enddate><creator>Uchida, Junji</creator><creator>Iwai, Tomoaki</creator><creator>Nishide, Shunji</creator><creator>Kabei, Kazuya</creator><creator>Kuwabara, Nobuyuki</creator><creator>Naganuma, Toshihide</creator><creator>Kumada, Norihiko</creator><creator>Takemoto, Yoshiaki</creator><creator>Nakatani, Tatsuya</creator><general>Başkent Üniversitesi</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IEBAR</scope></search><sort><creationdate>201904</creationdate><title>Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data</title><author>Uchida, Junji ; Iwai, Tomoaki ; Nishide, Shunji ; Kabei, Kazuya ; Kuwabara, Nobuyuki ; Naganuma, Toshihide ; Kumada, Norihiko ; Takemoto, Yoshiaki ; Nakatani, Tatsuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-10d4985ca1a3814739b93305ea60e81f4b45b70db2a696b2bb7dbf4f9d3c6c133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Tıp</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uchida, Junji</creatorcontrib><creatorcontrib>Iwai, Tomoaki</creatorcontrib><creatorcontrib>Nishide, Shunji</creatorcontrib><creatorcontrib>Kabei, Kazuya</creatorcontrib><creatorcontrib>Kuwabara, Nobuyuki</creatorcontrib><creatorcontrib>Naganuma, Toshihide</creatorcontrib><creatorcontrib>Kumada, Norihiko</creatorcontrib><creatorcontrib>Takemoto, Yoshiaki</creatorcontrib><creatorcontrib>Nakatani, Tatsuya</creatorcontrib><creatorcontrib>the Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Idealonline online kütüphane - Journals</collection><jtitle>Experimental and clinical transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uchida, Junji</au><au>Iwai, Tomoaki</au><au>Nishide, Shunji</au><au>Kabei, Kazuya</au><au>Kuwabara, Nobuyuki</au><au>Naganuma, Toshihide</au><au>Kumada, Norihiko</au><au>Takemoto, Yoshiaki</au><au>Nakatani, Tatsuya</au><au>Haberal,Mehmet</au><aucorp>the Department of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data</atitle><jtitle>Experimental and clinical transplantation</jtitle><addtitle>Exp Clin Transplant</addtitle><date>2019-04</date><risdate>2019</risdate><volume>17</volume><issue>2</issue><spage>190</spage><epage>195</epage><pages>190-195</pages><issn>1304-0855</issn><eissn>2146-8427</eissn><abstract>Here, we report our 1-year follow-up data of stable ABO-incompatible kidney transplant recipients who converted from mycophenolate mofetil plus a standard dose of a calcineurin inhibitor to everolimus plus low exposure to calcineurin inhibitors.
Our study included 17 recipients of ABO-incompatible kidney transplant procedures performed at our institution. At baseline and at 3 and 12 months after conversion, graft biopsies were performed to check for acute rejection and C4d deposition.
Treatment with everolimus was stopped due to adverse events in 8 patients (47.1%). Conversion to everolimus with calcineurin inhibitor minimization did not induce acute rejection or C4d deposition at 3 and 12 months after conversion in ABO-incompatible kidney transplant recipients in whom everolimus was maintained or stopped within 1 year after conversion.
Everolimus elicited no acute rejection and no C4d deposition, whether everolimus was maintained or stopped within 1 year after conversion, in ABO-incompatible kidney transplant recipients.</abstract><cop>Turkey</cop><pub>Başkent Üniversitesi</pub><pmid>30198840</pmid><doi>10.6002/ect.2017.0200</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1304-0855 |
| ispartof | Experimental and clinical transplantation, 2019-04, Vol.17 (2), p.190-195 |
| issn | 1304-0855 2146-8427 |
| language | eng |
| recordid | cdi_idealonline_journals_IDEAL_90891 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Tıp |
| title | Pilot Conversion Study From Mycophenolate Mofetil to Everolimus in Stable ABO-Incompatible Kidney Transplant Recipients: Analysis of 1-Year Follow-Up Data |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T10%3A16%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_ideal&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pilot%20Conversion%20Study%20From%20Mycophenolate%20Mofetil%20to%20Everolimus%20in%20Stable%20ABO-Incompatible%20Kidney%20Transplant%20Recipients:%20Analysis%20of%201-Year%20Follow-Up%20Data&rft.jtitle=Experimental%20and%20clinical%20transplantation&rft.au=Uchida,%20Junji&rft.aucorp=the%20Department%20of%20Urology,%20Osaka%20City%20University%20Graduate%20School%20of%20Medicine,%20Osaka,%20Japan&rft.date=2019-04&rft.volume=17&rft.issue=2&rft.spage=190&rft.epage=195&rft.pages=190-195&rft.issn=1304-0855&rft.eissn=2146-8427&rft_id=info:doi/10.6002/ect.2017.0200&rft_dat=%3Cpubmed_ideal%3E30198840%3C/pubmed_ideal%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30198840&rfr_iscdi=true |